Assessment of pharmacotherapy for negative symptoms of schizophrenia.
Negative symptoms in schizophrenia include diminished ability to communicate, motivate, and socialize as potentially debilitating aspects of the illness that are associated with long-term impairment. Despite such burden, the domain has been underrepresented in drug development and treatment research. In this article, we review research regarding pharmacotherapy for negative symptoms, with a focus on studies published during the past 2 years. Clearly positive studies were limited to N-methyl-D-aspartate agonists, while antipsychotics and antidepressants did not show substantial benefit, and cognitive enhancers have yielded mixed results. Proof-of-concept studies of other agents such as minocycline and omega fatty acids yielded promising, albeit preliminary findings that warrant replication. Study outcomes and designs are discussed along with implications for future research.
Hanson
Elizabeth
E
Schizophrenia Research Center, Department of Psychiatry, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, 19104, USA. elizabgh@upenn.edu
Healey
Kristin
K
Wolf
Daniel
D
Kohler
Christian
C
D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D018690:Excitatory Amino Acid Agonists / Q000627:therapeutic use*; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D018690:Excitatory Amino Acid Agonists; D016194:Receptors, N-Methyl-D-Aspartate
Neuropsychopharmacology. 2000 Oct;23(4):351-64
10989262
Psychiatry Res. 1989 Nov;30(2):119-23
2616682
Schizophr Res. 2007 Jul;93(1-3):109-16
17383857
J Clin Psychiatry. 2009 Apr;70(4):518-25
19358788
J Clin Psychiatry. 2007 Apr;68(4):604-10
17474817
Br J Psychiatry. 1987 Aug;151:145-51
3690102
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1810-5
18727948
Arch Gen Psychiatry. 2002 Oct;59(10):921-8
12365879
Neuroimage. 2006 Jan 15;29(2):409-16
16139525
Am J Psychiatry. 2005 Mar;162(3):495-506
15741466
Psychiatry Res. 2010 Feb 28;175(3):271-3
20045196
Psychopharmacol Bull. 1989;25(2):159-63
2602512
J Clin Psychopharmacol. 2009 Jun;29(3):267-71
19440081
J Clin Psychiatry. 2009 Dec;70(12):1674-80
19689921
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001257
16855961
Eur J Pharmacol. 1994 May 12;257(1-2):7-12
8082709
Isr J Psychiatry Relat Sci. 2009;46(3):213-20
20039523
J Clin Psychiatry. 2009 Oct;70(10):1416-23
19906345
J Clin Psychiatry. 2010 Feb;71(2):138-49
19895780
J Clin Psychiatry. 2006 Dec;67(12):1954-67
17194275
Int J Neuropsychopharmacol. 2010 May;13(4):451-60
19887019
Int Clin Psychopharmacol. 2001 Mar;16(2):87-92
11236073
Schizophr Res. 2009 Mar;108(1-3):245-51
19144501
Arch Gen Psychiatry. 2010 Feb;67(2):146-54
20124114
Hum Psychopharmacol. 2009 Apr;24(3):233-8
19330802
Schizophr Res. 2008 Dec;106(2-3):320-7
18799288
Schizophr Bull. 1987;13(2):261-76
3616518
Biol Psychiatry. 1995 Jul 1;38(1):22-33
7548469
Am J Psychiatry. 2006 May;163(5):790-9
16648318
Arch Gen Psychiatry. 2007 Dec;64(12):1356-66
18056543
CNS Drugs. 2009 Sep;23(9):781-92
19689168
Neuropsychopharmacology. 2009 Jul;34(8):1885-903
19339966
J Clin Psychiatry. 2009 Jun;70(6):801-9
19573479
Schizophr Res. 2010 Feb;116(2-3):101-6
19959338
Psychoneuroendocrinology. 2010 Sep;35(8):1142-7
20171784
J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S4-11
18334911
Schizophr Res. 2009 Feb;107(2-3):332-3
18995989
Neuropsychopharmacology. 2004 Jul;29(7):1363-73
15085092
J Clin Psychiatry. 2009 Apr;70(4):562-71
19192468
Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74
18978489
Schizophr Res. 2007 Sep;95(1-3):158-68
17628435
Neuropsychopharmacology. 2009 Apr;34(5):1322-9
19005465
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
8122957
Schizophr Bull. 2005 Jan;31(1):5-19
15888422
Hum Psychopharmacol. 2009 Aug;24(6):437-46
19637398
Int Clin Psychopharmacol. 2004 Mar;19(2):71-6
15076014